Shanghai MicroPort MedBot Group Co. Ltd. has announced a significant business update, highlighting the success of their core products in the surgical robotics sector. According to preliminary internal statistics, the cumulative order volume for their laparoscopic, orthopedic, and vascular interventional products has surpassed 130 units. Notably, the Toumai Laparoscopic Surgical Robot has been particularly successful, receiving over 70 cumulative commercial orders globally, with nearly 20 new orders obtained in 2025 alone. The company has also achieved over 50 commercial installations of the Toumai system. Furthermore, Toumai has been advancing large-scale, normalized clinical applications, with a growing number of human clinical surgeries performed worldwide. This progress marks a key milestone in the company's efforts to expand its presence in the global medical robotics market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.